The Oncology Institute, Inc.
TOINASDAQHealthcare● Active
$5.15
+$0.28(+5.79%)
Market Cap$515111901
P/E Ratio—
52W High$5.575
52W Low$2.015
The Oncology Institute, Inc. (TOI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TOI · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.02
Est. -$0.07 · +71.4%
Revenue
$0.15B
Est. $0.14B · +3.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
TOI reports quarterly as a NASDAQ-listed Medical - Care Facilities company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.07 | — | — | — | $0.16B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.07 | -$0.02 | +71.4% | $0.15B | $0.14B | +3.8% |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.08 | -$0.06 | +25.0% | $0.14B | $0.14B | +1.6% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.12 | -$0.14 | -16.7% | $0.14B | $0.14B | -2.3% |
| — Q3 FY2025 | Aug 13, 2025 | -$0.14 | -$0.14 | +0.0% | $0.12B | $0.12B | -2.2% |
| — Q2 FY2025 | May 14, 2025 | — | -$0.17 | — | $0.10B | — | — |
| ▼ Q1 FY2025 | Mar 24, 2025 | -$0.08 | -$0.14 | -75.0% | $0.10B | $0.11B | -8.1% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.07 | -$0.18 | -157.1% | $0.10B | $0.11B | -7.1% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.07
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.02
EPS Est.
-$0.07
EPS Surpr.
+71.4%
Revenue
$0.15B
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.08
EPS Surpr.
+25.0%
Revenue
$0.14B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.12
EPS Surpr.
-16.7%
Revenue
$0.14B
Q3 FY2025
Aug 13, 2025
EPS Actual
-$0.14
EPS Est.
-$0.14
EPS Surpr.
+0.0%
Revenue
$0.12B
Q2 FY2025
May 14, 2025
EPS Actual
-$0.17
EPS Est.
—
EPS Surpr.
—
Revenue
$0.10B
Q1 FY2025
Mar 24, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.08
EPS Surpr.
-75.0%
Revenue
$0.10B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.18
EPS Est.
-$0.07
EPS Surpr.
-157.1%
Revenue
$0.10B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q4 FY2027 | $0.00 | $0.01 | $0.01 | 1 |
| Q3 FY2027 | $-0.01 | $-0.01 | $-0.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q1 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 1 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +71.4% | $3.80 | $4.07 | +7.11% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +25.0% | $2.76 | $2.62 | -5.07% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -16.7% | $3.43 | $3.08 | -10.20% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +0.0% | $4.11 | $4.10 | -0.24% |
| — Q2 FY2025 | May 14, 2025 | — | $2.65 | $2.37 | -10.57% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -75.0% | $1.00 | $1.24 | +24.47% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -157.1% | $0.29 | $0.26 | -9.03% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -70.0% | $0.49 | $0.55 | +13.40% |
Q2 FY2026+7.11%
Report Date
May 7, 2026
EPS Beat/Miss
+71.4%
Price Before
$3.80
Price After
$4.07
Q1 FY2026-5.07%
Report Date
Mar 12, 2026
EPS Beat/Miss
+25.0%
Price Before
$2.76
Price After
$2.62
Q4 FY2025-10.20%
Report Date
Nov 13, 2025
EPS Beat/Miss
-16.7%
Price Before
$3.43
Price After
$3.08
Q3 FY2025-0.24%
Report Date
Aug 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$4.11
Price After
$4.10
Q2 FY2025-10.57%
Report Date
May 14, 2025
EPS Beat/Miss
—
Price Before
$2.65
Price After
$2.37
Q1 FY2025+24.47%
Report Date
Mar 24, 2025
EPS Beat/Miss
-75.0%
Price Before
$1.00
Price After
$1.24
Q4 FY2024-9.03%
Report Date
Nov 13, 2024
EPS Beat/Miss
-157.1%
Price Before
$0.29
Price After
$0.26
Q3 FY2024+13.40%
Report Date
Aug 13, 2024
EPS Beat/Miss
-70.0%
Price Before
$0.49
Price After
$0.55
Avg Beat Reaction+0.60%
Avg Miss Reaction+4.66%
Beat Rate3 / 8 quarters
Largest Move+24.47% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TOI ends December
The Oncology Institute, Inc. (TOI) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.02 — beating the analyst consensus of $-0.07 by +71.4%. TOI has beaten EPS estimates for 2 consecutive quarters. The next TOI earnings date is expected around September 1, 2026.
Each quarter, investors track TOI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TOI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TOI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TOI earnings · 5 questionsThe Oncology Institute, Inc.'s next earnings report is expected around September 1, 2026. TOI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TOI historically reports after market close (AMC).
TOI earnings datewhen is TOI earningsTOI next earnings datewhen does TOI report earningsTOI earnings calendar
▸ Source: FMP · The Oncology Institute, Inc. SEC filings · US GAAP · The Oncology Institute, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026